Roles of glutamate signaling in preclinical and/or mechanistic models of depression

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 4, 2012, Pages 688-704

  Tokita, Kenichi ^a,b   Yamaji, Takayuki ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

AMPA receptor; Animal models; Glutamate; Major depressive disorder; Metabotropic glutamate receptor; NMDA receptor

Indexed keywords

AGOMELATINE; AMITRIPTYLINE; AMPA RECEPTOR; CEFTRIAXONE; CLOZAPINE; DESIPRAMINE; ESCITALOPRAM; EXCITATORY AMINO ACID TRANSPORTER 2; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; IONOTROPIC RECEPTOR; KETAMINE; LITHIUM; MAGNESIUM; MEMANTINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RILUZOLE; TIANEPTINE; TRAXOPRODIL; UNINDEXED DRUG; VENLAFAXINE; ZINC;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE MODEL; DRUG SCREENING; ELECTROCONVULSIVE THERAPY; GENETIC MODEL; HUMAN; IMMUNOBLOTTING; MAJOR DEPRESSION; MENTAL PATIENT; MICROARRAY ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROCONVULSIVE THERAPY; GLUTAMATES; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84855557076     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.04.016     Document Type: Review

References (200)

1. Almeida RC, Felisbino CS, López MG, Rodrigues AL, Gabilan NH. Evidence for the involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav Brain Res 2006;168:318-22. (Pubitemid 43201950)
2. Almeida RF, Thomazi AP, Godinho GF, Saute JA, Wofchuk ST, Souza DO, et al. Effects of depressive-like behavior of rats on brain glutamate uptake. Neurochem Res 2010;35:1164-71.
3. Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006;71:1273-88.
4. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993;150:1731-3. (Pubitemid 23325960)
5. Ampuero E, Rubio FJ, Falcon R, Sandoval M, Diaz-Veliz G, Gonzalez RE, et al. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 2010;169:98-108.
6. Auer DP, Pütz B, Kraft E, Lipinski B, Schill J, Holsboer F. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000;47:305-13. (Pubitemid 30109243)
7. Bai F, Li X, Clay M, Lindstrom T, Skolnick P. Intra- and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 2001;70:187-92. (Pubitemid 33049928)
8. Bajkowska M, Brański P, Smialowska M, Pilc A. Effect of chronic antidepressant or electroconvulsive shock treatment on mGLuR1a immunoreactivity expression in the rat hippocampus. Pol J Pharmacol 1999;51:539-41. (Pubitemid 30052677)
9. Banasr M, Chowdhury GMI, Terwilliger R, Newton SS, Duman RS, Behar KL, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15:501-11.
10. Belmaker RH. The future of depression psychopharmacology. CNS Spectr 2008;13:682-7.
11. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007;17:172-9. (Pubitemid 44779190)
12. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007;32:1888-902. (Pubitemid 47258508)
13. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4. (Pubitemid 30109248)
14. Bespalov AY, van Gaalen MM, Sukhotina IA, Wicke K, Mezler M, Schoemaker H, et al. Behavioral characterization of themGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol 2008;592:96-102.
15. Black MD. Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 2005;179:154-63. (Pubitemid 40584805)
16. Block W, Träber F, von Widdern O, Metten M, Schild H, Maier W, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol 2009;12:415-22.
17. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005;25:3270-9. (Pubitemid 40471335)
18. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006;31:2405-14. (Pubitemid 44607058)
19. Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004;29:417-26. (Pubitemid 40075713)
20. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004;46:457-67. (Pubitemid 38224431)
21. Chaturvedi HK, Chandra D, Bapna JS. Interaction between N-methyl-D-aspartate receptor antagonists and imipramine in shock-induced depression. Indian J Exp Biol 1999;37:952-8. (Pubitemid 29482158)
22. Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs 2007;16:1365-77. (Pubitemid 47491407)
23. Chourbaji S, Vogt MA, Fumagalli F, Sohr R, Frasca A, Brandwein C, et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J 2008;22:3129-34.
24. Cieślik K, Klenk-Majewska B, Danilczuk Z, Wróbel A, Łupina T, Ossowska G. Influence of zinc supplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol Rep 2007;59:46-52. (Pubitemid 46522701)
25. Cryan JF, O'Leary OF. Neuroscience. A glutamate pathway to faster-acting antidepressants? Science 2010;329:913-4.
26. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 2003;17:2409-17. (Pubitemid 36793749)
27. da Silva FC, do Carmo de Oliveira Cito M, da Silva MI, Moura BA, de Aquino Neto MR, Feitosa ML, et al. Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. Brain Res Bull 2010;83:9-15.
28. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65:1-105. (Pubitemid 32479155)
29. Deak T, Bellamy C, D'Agostino LG, Rosanoff M, McElderry NK, Bordner KA. Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide. Behav Brain Res 2005;160:125-34.
30. Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M. NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol Biochem Behav 1997;58:261-8. (Pubitemid 27334381)
31. 11C]ABP688 PET and postmortem study. Am J Psychiatry 2011;168:727-34.
32. Di Liberto V, Bonomo A, Frinchi M, Belluardo N, Mudò G. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience 2010;165:863-73.
33. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999;51:7-61. (Pubitemid 29113865)
34. Domino EF. Taming the ketamine 1965. Anesthesiology 2010;113:678-84.
35. Du J, Machado-Vieira R, Maeng S, Martinowich K, Manji HK, Zarate JCA. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov Today Ther Strat 2006;3:519-26. (Pubitemid 46076181)
36. Dybala M, Siwek A, Poleszak E, Pilc A, Nowak G. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J Neural Transm 2008;115:1519-20.
37. Eby 3rd GA, Eby KL. Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses 2010;74:649-60.
38. El Khoury A, Gruber SHM, Mørk A, Mathé AA. Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:535-40.
39. Elfving B, Plougmann PH, Muller HK, Mathé AA, Rosenberg R, Wegener G. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010;13:563-72.
40. Elizalde N, Pastor PM, Garcia-Garcia AL, Serres F, Venzala E, Huarte J, et al. Regulation of markers of synaptic function in mouse models of depression: chronic mild stress and decreased expression of VGLUT1. J Neurochem 2010;114:1302-14.
41. Engin E, Treit D, Dickson CT. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009;161:359-69.
42. Esplugues JV. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002;135:1079-95. (Pubitemid 34259107)
43. Farley S, Apazoglou K, Witkin JM, Giros B, Tzavara ET. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 2010;13:1207-18.
44. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007;30:136-44. (Pubitemid 46871863)
45. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:70-5.
46. Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, Wang Z, Kyle PB, Hasler G, et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:279-83.
47. Frye MA, Tsai GE, Huggins T, Coyle JT, Post RM. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2007;61:162-6. (Pubitemid 46072777)
48. Fumagalli F, Pasini M, Sartorius A, Scherer R, Racagni G, Riva MA, et al. Repeated electroconvulsive shock (ECS) alters the phosphorylation of glutamate receptor subunits in the rat hippocampus. Int J Neuropsychopharmacol 2010;13:1255-60.
49. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Andreazza AC, Stertz L, et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clin Pharmacol Toxicol 2008a;103:502-6.
50. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008b;32:140-4.
51. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Stertz L, Kapczinski F, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:450-5.
52. Garcia-Garcia AL, Elizalde N, Matrov D, Harro J, Wojcik SM, Venzala E, et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol Psychiatry 2009;66:275-82.
53. Gołembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 2000;52:441-8. (Pubitemid 32045907)
54. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009a;61:105-23.
55. Hashimoto K. Conmments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective NMDA antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder". J Clin Psychopharmacol 2009b;29:411-2.
56. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009c;9:197-204.
57. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010;64:341-57.
58. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1558-68.
59. Hashimoto K. Role of mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Rev Neurother 2011;11:33-6.
60. Hashimoto K, Ishima T. A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation factor eIF4AI. PLoS One 2010;5:e15430.
61. Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006;12:3857-76. (Pubitemid 44560699)
62. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-6. (Pubitemid 350060893)
63. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007;64:193-200. (Pubitemid 46220776)
64. He Y, Janssen WG, Morrison JH. Synaptic coexistence of AMPA and NMDA receptors in the rat hippocampus: a postembedding immunogold study. J Neurosci Res 1998;54:444-9. (Pubitemid 28507023)
65. Ho Y, Liu T, Tai M, Wen Z, Chow RS, Tsai Y, et al. Effects of olfactory bulbectomy on NMDA receptor density in the rat brain. Brain Res 2001;900:214-8.
66. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
67. Joca SR, Ferreira FR, Guimarães FS. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 2007;10:227-49. (Pubitemid 47037199)
68. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006;6:61-7. (Pubitemid 43103820)
69. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742-55. (Pubitemid 351957932)
70. Karasawa J, Shimazaki T, Kawashima N, Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005;1042:92-8.
71. Karolewicz B, Feyissa AM, Chandran A, Legutko B, Ordway GA, Rajkowska G, et al. Glutamate receptors expression in postmortem brain from depressed subjects. Biol Psychiatry 2009;65:177S.
72. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci 2002;5(Suppl):1039-42. (Pubitemid 35247194)
73. Kessler RC, Wang PS. The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008;29:115-29. (Pubitemid 351600402)
74. Kharazia VN, Phend KD, Rustioni A, Weinberg RJ. EM colocalization of AMPA and NMDA receptor subunits at synapses in rat cerebral cortex. Neurosci Lett 1996;210:37-40. (Pubitemid 26176850)
75. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982;232:299-304. (Pubitemid 13124834)
76. Kłak K, Pałucha A, Brański P, Sowa M, Pilc A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids 2007;32:169-72. (Pubitemid 46198739)
77. Kłodzińska A, Chojnacka-Wójcik E, Pałucha A, Brański P, Popik P, Pilc A. Potential antianxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 1999;38:1831-9. (Pubitemid 29509721)
78. Knapp RJ, Goldenberg R, Shuck C, Cecil A, Watkins J, Miller C, et al. Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. Eur J Pharmacol 2002;440:27-35. (Pubitemid 34312035)
79. Kos T, Popik P, Pietraszek M, Schäfer D, Danysz W, Dravolina O, et al. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol 2006;16:297-310.
80. Kroczka B, Branski P, Palucha A, Pilc A, Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull 2001;55:297-300. (Pubitemid 32722173)
81. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214. (Pubitemid 24081509)
82. Krystal JH, Perry Jr EB, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 2005;62:985-94.
83. Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010;24:669-93.
84. Lanni C, Govoni S, Lucchelli A, Boselli C. Depression and antidepressants: molecular and cellular aspects. Cell Mol Life Sci 2009;66:2985-3008.
85. Legutko B, Szewczyk B, Pomierny-Chamiolo L, Nowak G, Pilc A. Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep 2006;58:427-30. (Pubitemid 44111079)
86. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000;47:586-93. (Pubitemid 30169251)
87. Li X, Tizzano JP, Griffey K, Clay M, Lindstrom T, Skolnick P. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001;40:1028-33. (Pubitemid 32530609)
88. Li X, Witkin JM, Need AB, Skolnick P. Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol 2003;23:419-30. (Pubitemid 36676283)
89. Li X, Need AB, Baez M, Witkin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006;319:254-9. (Pubitemid 44455130)
90. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-64.
91. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011;69:754-61.
92. Lisanby SH, Belmaker RH. Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). Depress Anxiety 2000;12:178-87.
93. Little A. Treatment-resistant depression. Am Fam Physician 2009;80:167-72.
94. Loftis JM, Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol Ther 2003;97:55-85. (Pubitemid 35477804)
95. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol 2006;100:481-99. (Pubitemid 47050869)
96. López-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009;15:1563-86.
97. Machado-Vieira R, Salvadore G, DiazGranados N, Zarate Jr CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009;123:143-50.
98. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349-52. (Pubitemid 351146651)
99. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998;97:302-8. (Pubitemid 28179268)
100. Maier SF. Learned helplessness and animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:435-46. (Pubitemid 14051222)
101. Malkesman O, Weller A. Two different putative genetic animal models of childhood depression - a review. Prog Neurobiol 2009;88:153-69.
102. Martínez-Turrillas R, Del Río J, Frechilla D. Sequential changes in BDNF mRNA expression and synaptic levels of AMPA receptor subunits in rat hippocampus after chronic antidepressant treatment. Neuropharmacology 2005;49:1178-88. (Pubitemid 41608642)
103. Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricasole A, Scaccianoce S, et al. Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 2002;42:1008-15. (Pubitemid 34786554)
104. Matrisciano F, Panaccione I, Zusso M, Giusti P, Tatarelli R, Iacovelli L, et al. Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depression: a new strategy to shorten the latency of antidepressant medication? Mol Psychiatry 2007;12:704-6. (Pubitemid 47172692)
105. Matrisciano F, Caruso A, Orlando R, Marchiafava M, Bruno V, Battaglia G, et al. Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 2008;55:525-31.
106. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998;37:124-9. (Pubitemid 28171767)
107. McArthur R, Borsini F. Animal models of depression in drug discovery: a historical perspective. Pharmacol Biochem Behav 2006;84:436-52. (Pubitemid 44308553)
108. Michael-Titus AT, Bains S, Jeetle J, Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 2000;100:681-4.
109. Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6 J mice. Biol Psychiatry 2007;61:250-2. (Pubitemid 46072785)
110. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby Jr CR, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1155-8. (Pubitemid 43928219)
111. Mitchell ND, Baker GB. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 2010;122:192-210.
112. Mitsukawa K, Mombereau C, Lötscher E, Uzunov DP, van der Putten H, Flor PJ, et al. Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology 2006;31:1112-22. (Pubitemid 43971829)
113. Miura H, Ozaki N, Sawada M, Isobe K, Ohta T, Nagatsu T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008;11:198-209. (Pubitemid 351874183)
114. Molina-Hernández M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008a;32:380-6. (Pubitemid 351178956)
115. Molina-Hernández M, Tellez-Alcántara NP, Pérez-Garcia J, Olivera-Lopez JI, Jaramillo MT. Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1129-35. (Pubitemid 43928236)
116. Molina-Hernández M, Tellez-Alcántara NP, Pérez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2008b;32:1660-6.
117. Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 2009;157:1301-17.
118. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993;72:394-7. (Pubitemid 23188507)
119. Moutsimilli L, Farley S, Dumas S, El Mestikawy S, Giros B, Tzavara ET. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 2005;49:890-900. (Pubitemid 41483895)
120. Muhonen LH, Lönnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008;69:392-9. (Pubitemid 351549391)
121. Musazzi L, Milanese M, Farisello P, Zappettini S, Tardito D, Barbiero VS, et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 2010;5:e8566.
122. Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:259-64.
123. Nakamura K, Tanaka Y. Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology (Berl) 2001;158:205-12. (Pubitemid 33020840)
124. Naylor P, Stewart CA, Wright SR, Pearson RC, Reid IC. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Brain Res Mol Brain Res 1996;35:349-53. (Pubitemid 26036768)
125. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 2003;61:159-64. (Pubitemid 36794273)
126. Nowak G, Szewczyk B, Pilc A. Zinc and depression. An update. Pharmacol Rep 2005;57:713-8.
127. Nudmamud-Thanoi S, Reynolds GP. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 2004;372:173-7. (Pubitemid 39505251)
128. O'Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009;14:511-22.
129. Oh S, Hoshi K, Ho IK. Role of NMDA receptors in pentobarbital tolerance/dependence. Neurochem Res 1997;22:767-74. (Pubitemid 27300633)
130. O'Mahony CM, Bravo JA, Dinan TG, Cryan JF. Comparison of hippocampal metabotropic glutamate receptor 7 (mGlu7) mRNA levels in two animal models of depression. Neurosci Lett 2010;482:137-41.
131. O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets 2007;8:603-20. (Pubitemid 46794920)
132. O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord 2004;3:181-94. (Pubitemid 38854913)
133. Overstreet DH, Friedman E, Mathé AA, Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005;29:739-59. (Pubitemid 40762598)
134. Palucha A, Klak K, Branski P, van der Putten H, Flor PJ, Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) 2007;194:555-62. (Pubitemid 47492987)
135. Pałucha A, Tatarczyńska E, Brański P, Szewczyk B, Wierońska JM, Kłak K, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004;46:151-9. (Pubitemid 37532823)
136. Pałucha A, Brański P, Szewczyk B, Wierońska JM, Kłak K, Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005;81:901-6. (Pubitemid 41187826)
137. Pałucha A, Brański P, Kłak K, Sowa M. Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity. Pharmacol Rep 2007;59:525-30.
138. Pałucha-Poniewiera A, Brański P, Lenda T, Pilc A. The antidepressant-like action of mGlu7 receptor agonist, N, N′- bis(diphenylmethyl)-1,2-ethanediamine (AMN082), is serotonin-dependent. J Pharmacol Exp Ther 2010;334:1066-74.
139. Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47. (Pubitemid 46238036)
140. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723. (Pubitemid 47532143)
141. Paul IA, Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003;1003:250-72. (Pubitemid 38083061)
142. Pilc A, Kłodzinska A, Brański P, Nowak G, Pałucha A, Szewczyk B, et al. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 2002;43:181-7. (Pubitemid 35247606)
143. Pittaluga A, Raiteri L, Longordo F, Luccini E, Barbiero VS, Racagni G, et al. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 2007;53:27-36. (Pubitemid 47125945)
144. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008;22:761-86.
145. Poleszak E. Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transm 2007;114:1129-34. (Pubitemid 47313166)
146. Poleszak E, Szewczyk B, Kȩdzierska E, Wlaź P, Pilc A, Nowak G. Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav 2004;78:7-12. (Pubitemid 38670508)
147. Poleszak E, Wlaź P, Kȩdzierska E, Radziwon-Zaleska M, Pilc A, Fidecka S, et al. Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacol Rep 2005;57:654-8.
148. Poleszak E, Wlaź P, Kȩdzierska E, Nieoczym D, Wyska E, Szymura-Oleksiak J, et al. Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacol Rep 2006;58:746-52. (Pubitemid 44741694)
149. Poleszak E, Wlaź P, Kȩdzierska E, Nieoczym D, Wróbel A, Fidecka S, et al. NMDA/ glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 2007;88:158-64. (Pubitemid 350115999)
150. Pralong E, Magistretti P, Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog Neurobiol 2002;67:173-202. (Pubitemid 34880131)
151. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008;28:631-7.
152. Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2008;10:385-400.
153. Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol 2010;25:117-31.
154. Reagan LP, Rosell DR, Wood GE, Spedding M, Muñoz C, Rothstein J, et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc Natl Acad Sci U S A 2004;101:2179-84. (Pubitemid 38229035)
155. Réus GZ, Stringari RB, Kirsch TR, Fries GR, Kapczinski F, Roesler R, et al. Neurochemical and behavioural effects of acute and chronic memantine administration in rats: further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull 2010;81:585-9.
156. Robichaud M, Beauchemin V, Lavoie N, Dennis T, Debonnel G. Effects of bilateral olfactory bulbectomy on N-methyl-D-aspartate receptor function: autoradiographic and behavioral studies in the rat. Synapse 2001;42:95-103.
157. Rogóż Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002;42:1024-30. (Pubitemid 34790257)
158. Rosa AO, Lin J, Calixto JB, Santos AR, Rodrigues AL. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 2003;144:87-93. (Pubitemid 37011169)
159. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-7. (Pubitemid 40101145)
160. Ryan B, Musazzi L, Mallei A, Tardito D, Gruber SH, El Khoury A, et al. Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene-environment rat model of depression. Int J Neuropsychopharmacol 2009;12:553-9.
161. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. J Clin Psychiatry 2009a;70:1473-5.
162. Sanacora G. Do glutamatergic agents represent a new class of antidepressant drugs? Part 2. J Clin Psychiatry 2009b;70:1604-5.
163. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-13. (Pubitemid 38890805)
164. Sattler R, Rothstein JD. Targeting an old mechanism in a new disease-protection of glutamatergic dysfunction in depression. Biol Psychiatry 2007;61:137-8. (Pubitemid 46072793)
165. Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61.
166. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997;17:7503-22. (Pubitemid 27413281)
167. Shigeri Y, Seal RP, Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev 2004;45:250-65. (Pubitemid 38802874)
168. Short KR, Tabakoff B. Chronic barbiturate treatment increases NMDA receptors but decreases kainate receptors in mouse cortex. Eur J Pharmacol 1993;230:111-4. (Pubitemid 23024990)
169. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30:563-9.
170. Skuza G, Rogóż Z. Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats. Pol J Pharmacol 2003;55:1149-52. (Pubitemid 38128955)
171. Skuza G, Rogóż Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol 2006;57:217-29. (Pubitemid 44077747)
172. Śmiałowska M, Szewczyk B, Brański P, Wierońska JM, Pałucha A, Bajkowska M, et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 2002;42:1016-23. (Pubitemid 34786555)
173. Smolders I, Clinckers R, Meurs A, De Bundel D, Portelli J, Ebinger G, et al. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 2008;54:1017-28.
174. Sowa-Kućma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, et al. Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm 2008;115:1621-8.
175. Svenningsson P, Bateup H, Qi H, Takamiya K, Huganir RL, Spedding M, et al. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 2007;26:3509-17. (Pubitemid 350243523)
176. Szewczyk B, Poleszak E, Sowa-Kućma M, Siwek M, Dudek D, Ryszewska-Pokraśniewicz B, et al. Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep 2008;60:588-99.
177. Szewczyk B, Poleszak E, Sowa-Kućma M, Wróbel A, Slotwiński S, Listos J, et al. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 2010;39:205-17.
178. Takahashi K, Murasawa H, Yamaguchi K, Yamada M, Nakatani A, Yoshida M, et al. Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behav Brain Res 2011;216:46-52.
179. Tan CH, He X, Yang J, Ong WY. Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function? Exp Brain Res 2006;170:448-56.
180. Taniguchi S, Nakazawa T, Tanimura A, Kiyama Y, Tezuka T, Watabe AM, et al. Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour. EMBO J 2009;28:3717-29.
181. Tatarczyńska E, Klodzińska A, Chojnacka-Wójcik E, Pałucha A, Gasparini F, Kuhn R, et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001;132:1423-30. (Pubitemid 32281030)
182. Tatarczyńska E, Pałucha A, Szewczyk B, Chojnacka- Wójcik E, Wierońska J, Pilc A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1- aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Pol J Pharmacol 2002;54:707-10. (Pubitemid 36124524)
183. Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-77.
184. Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007;25:281-90. (Pubitemid 46096241)
185. Tordera RM, Garcia-García AL, Elizalde N, Segura V, Aso E, Vebzala E, et al. Chronic stress and impaired glutamate function elicit a depressive-like phenotype and common changes in gene expression in the mouse frontal cortex. Eur Neuropsychopharmacol 2011;21:23-32.
186. Toth E, Gersner R, Wilf-Yarkoni A, Raizel H, Dar DE, Richter-Levin G, et al. Age-dependent effects of chronic stress on brain plasticity and depressive behavior. J Neurochem 2008;107:522-32.
187. Valentine GW, Sanacora G. Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol 2009;78:431-9.
188. Webster HH, Flores G, Marcotte ER, Cecyre D, Quirion R, Srivastava LK. Olfactory bulbectomy alters NMDA receptor levels in the rat prefrontal cortex. Synapse 2000;37:159-62. (Pubitemid 30447946)
189. Wierońska JM, Szewczyk B, Branski P, Palucha A, Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002;23:213-6.
190. Wierońska JM, Legutko B, Dudys D, Pilc A. Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol Rep 2008;60:844-55.
191. Wierońska JM, Brański P, Szewczyk B, Pałucha A, Papp M, Gruca P, et al. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol J Pharmacol 2001;53:659-62.
192. Wierońska JM, Kłak K, Pałucha A, Brański P, Pilc A. Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res 2007;1184:88-95. (Pubitemid 350160601)
193. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997;134:319-29. (Pubitemid 28023396)
194. Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, et al. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane- 2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorg Med Chem 2006;14:4193-207. (Pubitemid 44287810)
195. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002;71:341-4.
196. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006;186:587-93. (Pubitemid 43855846)
197. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006a;63:856-64. (Pubitemid 44188478)
198. Zarate Jr CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006b;163:153-5. (Pubitemid 43050119)
199. Zarate Jr C, Machado-Viera R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood diorders? Harv Rev Psychiatry 2010;18:293-303.
200. Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2010;58:465-73.